Evogene shareholders approve cooperation agreement

Evogene's meeting disclosures are incorporated by reference into its Form F-3 and Form S-8 registration statements.

Available on EDGAR 11/10/2026 - 08:31 AM EST Accepted by SEC EDGAR 11/10/2026 - 08:31 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Evogene Ltd. (EVGN) held a special general meeting on November 10, 2026, where shareholders approved Proposals Nos. 1–3 by the requisite vote. Shareholders also approved a Cooperation Agreement between L.I.A. Pure Capital Ltd. and Invest-Pro Shukai Hon Ltd., on one hand, and Evogene on the other; the agreement became effective at the end of the meeting. The board comprises Nir Nimrodi, Leon Y. Recanati, Dr. Adi Zuluf-Shani, Oz Adler, Itai Maroz, Shahar Zadok, and Ofer Haviv, the company's President and CEO.

Key Figures

Meeting date: November 10, 2026 Proposals approved: Proposals Nos. 1–3 Board composition: 7 directors

3 metrics

Meeting date November 10, 2026 Special general meeting

Proposals approved Proposals Nos. 1–3 Approved by the requisite shareholder vote

Board composition 7 directors Following the special general meeting

Key Terms

special general meeting, Cooperation Agreement, incorporated by reference

3 terms

special general meeting regulatory

"held a special general meeting of its shareholders"

A special general meeting is a one-off meeting of a company's shareholders called outside the regular annual meeting to decide on specific, often urgent matters—such as major transactions, changes to the company’s rules, or board appointments. It matters to investors because the votes taken can materially change ownership, strategy, or the company’s finances, making the meeting like an emergency town hall where decisions can immediately affect the value and control of their investment.

Cooperation Agreement regulatory

"The Cooperation Agreement ... was approved and effective"

A cooperation agreement is a formal contract between two or more organizations that lays out who will do what, how resources and responsibility are shared, how benefits or costs are divided, and how disputes or exits are handled. Like two chefs agreeing on a shared recipe and kitchen duties, it matters to investors because it can create new revenue paths, shift costs or risks, affect who controls key assets or technologies, and change a company’s future growth prospects.

incorporated by reference regulatory

"The contents of this Report ... is incorporated by reference"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did EVGN shareholders approve at the November 2026 meeting?

EVGN shareholders approved Proposals Nos. 1–3 by the requisite vote at the November 10, 2026 special general meeting. They also approved the Cooperation Agreement between Evogene and L.I.A. Pure Capital Ltd. and Invest-Pro Shukai Hon Ltd.; it became effective at the end of the meeting.

Who is on EVGN's board after the special general meeting?

The board comprises Nir Nimrodi, Leon Y. Recanati, Dr. Adi Zuluf-Shani, Oz Adler, Itai Maroz, Shahar Zadok, and Ofer Haviv, who is the company's President and CEO.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER 

PURSUANT TO RULE 13a-16 OR 15d-16 OF 

THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2026

Commission File Number 001-36187

EVOGENE LTD. 

(Translation of Registrant’s Name into English)

13 Gad Feinstein Street, Park Rehovot, Rehovot

7638517, Israel 

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒        Form 40-F ☐

CONTENTS

On November 10, 2026, Evogene Ltd., or the Company, held a special general meeting of its shareholders, or the Meeting, at its offices.  At the Meeting, shareholders voted on the proposals detailed in the Company’s proxy statement for the Meeting that was attached as Exhibit 99.1 to a Report of Foreign Private Issuer on Form 6-K that the Company furnished to the Securities and Exchange Commission on October 6, 2026.

At the Meeting, Proposals Nos. 1-3 were approved by the requisite vote of the Company’s shareholders. The Cooperation Agreement, between L.I.A. Pure Capital Ltd., Invest-Pro Shukai Hon Ltd., on one hand, and the Company, on the other hand, was approved and effective as of the end of the Meeting, the Company’s board of directors is comprised of (a) Mr. Nir Nimrodi, (b) Mr. Leon Y. Recanati, (c)Dr. Adi Zuluf-Shani, (d) Mr. Oz Adler, (e) Mr. Itai Maroz, (f) Mr. Shahar Zadok and (g) Mr. Ofer Haviv, the Company’s President and CEO.

The contents of this Report of Foreign Private Issuer on Form 6-K (this “Form 6-K”) is incorporated by reference in the registration statements on Form F-3 (Securities and Exchange Commission File No.’s 333-277565 and 333-294650), and Form S-8 (SEC File No.’s 333-193788, 333-201443, 333-203856, 333-259215, 333-286197 and 333-294648) of the Company, and will be a part thereof from the date on which this Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: November 10, 2026 EVOGENE LTD.
(Registrant)

By: /s/ Ofer Haviv  
——————————————
Ofer Haviv
President and CEO